Vifor Pharma Group
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vifor Pharma Group
Two European companies - the Belgian-Dutch biotech Argenx and Calliditas of Sweden - are going it alone to commercialize their just-approved rare disease therapies in the US.
Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.
Although ANG-3777, partnered with Vifor, missed its primary endpoint in cardiovascular surgery patients at risk for acute kidney injury, the companies will consider a path forward based on a renal events measure.
After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
- Galenica Group
- Relypsa, Inc.
- Vifor Pharma
- Vifor-Fresenius Medical Care Renal Pharma Ltd.
- OM Pharma